Settlement Structure: Claims Made
Active: Closed
Closed Settlement Statement:
According to court documents, the claim submission deadline has passed. Please contact the claims administrator if you have any questions
Case Summary:Johnson & Johnson and Janssen Biotech, Inc. are putting up $25 million to settle an antitrust class action centering on anticompetitive actions they allegedly took to protect their drug Remicade (infliximab) from competition. The complaint alleged the companies violated federal and state antitrust laws and consumer protection laws by attempting to keep new entrants out of the market for infliximab, causing consumers and third-party payors to pay more for the drug.
Docket Number:2:17-cv-04326-KSM
Company: Johnson & Johnson
Filing Deadline: November 30, 2022
Class Period: April 5, 2016 to February 28, 2022
Objection Deadline: November 30, 2022
Exclusion Deadline: November 30, 2022
Final Approval Hearing: February 27, 2023
Proof of Purchase:If your claim is for $1,000 or more, you must provide documentation. The Settlement Administrator may also require documentation for claims below that amount if there is a dispute over a material fact in the claim.
Eligibility:You may be eligible if you are a person or entity who in the US or its territories who indirectly bought, paid for, or provided reimbursement for some or all of the purchase price of Remicade between April 5, 2016 and February 28, 2022. See the Notice for exclusions.
Typical Settlement Amount:Share of the net settlement fund, according to a plan of allocation and distribution, based on membership in one of the three groups below:
- Class members who live or have their principal place of business in a Selected State will have a claim equal to their total Remicade purchases and reimbursements.
- Class members who do not live or have their principal place of business in a Selected State but who did buy or reimburse for Remicade in one or more of the Selected States will have a claim equal to their total Remicade purchases and reimbursements in the Selected States and 1% of their total Remicade purchases and reimbursements outside of those states.
- Class members who do not live or have their principal place of business in a Selected State and who did not buy or reimburse for Remicade in any of the Selected States will have a claim of 1% of their total Remicade purchases or reimbursements.
The Selected States are Arizona, Arkansas, California, the District of Columbia, Florida, Hawaii, Iowa, Kansas, Maine, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin.
Total Settlement Amount: $25,000,000
Class Representative Proposed Incentive Fee:Unknown
Law Firm:
Robbins Geller Rudman & Dowd
Claim Form: Remicade Antitrust Settlement Claim Form
Case Name: In re Remicade Antitrust Litigation
Settlement Website: Remicade Antitrust Settlement Website
Claims Administrator:
Gilardi & Co., LLC
Remicade Antitrust Litigation
c/o Gilardi & Co
Settlement Administrator
P.O. Box 6175
Novato, CA 94947-6175
info@RemicadeSettlement.com
888-859-1912
